A tumor may release too little DNA into the sampled blood for a test to detect. A negative plasma result needs to be read with the test, sample and clinical setting in mind.
A primary study across multiple cancers found that circulating tumor DNA detection varied by cancer type and stage. Assay capability and biological availability of tumor DNA both affect a result. A negative plasma call can reflect low shedding, limited sampled material or absence of the tracked signal, rather than proving that no tumor exists. This concept explains a limitation; it does not specify which additional clinical test an individual should receive.
Showing the technology this term belongs to: Liquid biopsy (ctDNA).
Shares Finite-molecule sampling in blood tests, Evidence from measurement to patient benefit, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Evidence from measurement to patient benefit, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/